In an interview with Pharmacy Times, AZA Allsop, MD, PhD, assistant professor of psychiatry at Yale and Howard University and head of research for Beckley Retreats, discussed the distinction between psychedelics as targeted clinical interventions and their broader wellness applications. Allsop explained that psychedelic-assisted psychotherapy for conditions like posttraumatic stess disorder (PTSD), depression, and substance use disorders requires a structured therapeutic framework, including preparation, supervised administration, and integration. The discussion followed the signing of an executive order by President Donald Trump, which seeks to accelerate the regulatory clearance of psychedelic medicines.
He noted that wellness-oriented use in people without a clinical diagnosis may warrant a different regulatory pathway. Allsop also addressed the FDA Breakthrough Therapy designation, explaining that while it can shorten development and review timelines, it does not guarantee approval, citing 3,4-methylenedioxymethamphetamine (MDMA) as an example. Finally, he discussed why naturalistic, group-based research settings, such as those used by Beckley Retreats, offer insight that highly controlled clinical trials cannot, particularly around real-world implementation and non-clinical outcomes like burnout, longevity, and social connectedness.
Pharmacy Times: The Executive Order is largely focused on psychedelics as a treatment for veterans with PTSD. How do you distinguish between psychedelics as a targeted clinical intervention versus their broader preventative and wellness applications, and why does that distinction matter for how the field develops?
AZA Allsop, MD, PhD: That's a great question. As a psychiatrist, when I think about treating those who are suffering from mental health conditions and those who are vulnerable, there's a certain level of accountability and responsibility that has to be in place. In this case, we're talking about psychedelic-assisted psychotherapy, and there's a whole therapeutic component to the delivery of the psychedelic. In psychiatry, we've long searched for new treatments that could really have a meaningful impact, and the early evidence from psychedelics within a clinical context seems to really show that they are doing some remarkable things for conditions like PTSD, depression, and even substance use disorders. I think this is a way to really help accelerate that development and make sure that all of the right therapeutic pieces are in place: preparation, the actual clinical administration of the compound in a supportive setting, and then the integration. However, I think psychedelics offer opportunities beyond simply treating those who have severe challenges with mental health, and there's a real argument to be made that they can enhance wellness in people who have mild symptoms or who don't meet any clinical diagnosis at all. I think that might be a different path for regulation and development than for purely clinical administration. If we don't also explore these wellness components, we are missing a potential opportunity to enhance the way our society functions and enhance the way that individuals experience life, particularly as they get older and move through different phases and cycles of older adult development.
Pharmacy Times: Several psychedelics have received Breakthrough Therapy designation from the FDA. What does that designation actually signal to clinicians and researchers, and what are its practical implications for the drug development pipeline?
Key Takeaways
- Psychedelics used for diagnosed conditions like PTSD and depression likely require a different regulatory and clinical framework than wellness-focused use in non-diagnosed individuals.
- Breakthrough Therapy designation can accelerate development timelines but does not guarantee eventual FDA approval, as seen with MDMA.
- Research conducted in naturalistic, group-based settings is providing evidence that complements traditional controlled clinical trials, particularly for real-world implementation.
Allsop: The Breakthrough Therapy designation, I think, signals to us as clinicians and researchers that there is a real, legitimate effort and push for the development of these compounds within the clinical context as medicines. It adds some legitimacy and gives it more of a mainstream space to really discuss what the potential benefits and potential harms are within clinical development. Practically, it's supposed to mean shorter timelines for review, shorter timelines for development and approval, and the ability to move from a phase 1 study, where we're looking at safety, to actually being able to prescribe these medications and deliver them within a clinical context. Now, there's still a lot that has to be figured out in terms of, once a compound or certain treatment modality is approved, how do we actually get it to people in a way that's equitable, accessible, and affordable? But at least this allows the development of the medicine to happen on a much faster timeline. It's not a foolproof process, though. MDMA was granted Breakthrough Therapy designation and had phase 3 results but did not actually get approval in that first round. So while breakthrough designation helps the process, it's not a foolproof way of assuring that a compound will be approved at the end of a phase 3 trial.
Pharmacy Times: Much of the landmark psychedelic research has taken place in highly controlled, individual clinical settings. Why does research conducted in naturalistic group settings add something meaningful to that existing body of evidence?
Allsop: Within our Western clinical context, we really tend to be very reductionist and try to understand very precisely what mechanisms are at play—how a certain pharmacological compound or certain psychotherapeutic mechanism actually interacts with the human system to give us the outcomes and results that we want. That means most clinical trials have been done in very controlled, sterile settings, and that helps us from a scientific perspective, but it often leads to challenges when we try to implement these treatments in the real world. As an integrative psychiatrist, I think there's an opportunity to expand how we think about clinical delivery of compounds. The kind of work that we do at a setting like Beckley, which is a non-clinical space, is still very aware of safety and risk and has a preparation phase, a ceremony, and then also an integration phase. I think there's an opportunity there to really understand how that treatment and delivery space could be leveraged within a potential clinical application, but also, as we were talking about, from broader wellness applications, like burnout or longevity, even social connectedness and nature-relatedness. These are all non-clinical outcomes that are still very meaningful. So I think understanding how psychedelics work within a very controlled clinical context, but also how they work in more naturalistic contexts, like retreat settings or ceremonial settings, allows us to have a broader view of their potential for human development.
